Lataa...
The BET-bromodomain inhibitor JQ1 mitigates vemurafenib drug resistance in melanoma
Inhibition of BRAF improves therapeutic efficacy of BRAF-mutant melanoma. However, drug resistance to BRAF inhibitor is inevitable, and the drug resistance mechanisms still remain to be elucidated. Here, BRAF(V600E) mutant cells A375 and SK-MEL-28 were chosen and treated with BRAF inhibitor vemurafe...
Tallennettuna:
| Julkaisussa: | Melanoma Res |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Lippincott Williams & Wilkins
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6221393/ https://ncbi.nlm.nih.gov/pubmed/30192303 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CMR.0000000000000497 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|